JPY1,460.00
1.46% day before yesterday
Tokyo, May 02, 08:15 am CET
ISIN
JP3942400007
Symbol
4503
Index
Sector
Industry

Astellas Pharma Target price 2025 - Analyst rating & recommendation

Astellas Pharma Classifications & Recommendation:

Buy
38%
Hold
54%
Sell
8%

Astellas Pharma Price Target

Target Price JPY1,695.83
Price JPY1,458.00
Potential
Number of Estimates 12
12 Analysts have issued a price target Astellas Pharma 2026 . The average Astellas Pharma target price is JPY1,695.83. This is higher than the current stock price. The highest price target is
JPY2,200.00 50.89%
register free of charge
, the lowest is
JPY1,300.00 10.84%
register free of charge
.
A rating was issued by 13 analysts: 5 Analysts recommend Astellas Pharma to buy, 7 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Astellas Pharma stock has an average upside potential 2026 of . Most analysts recommend the Astellas Pharma stock at Hold.

Sales and Margin forecast 2026, 2027 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Revenue Billion JPY 1,912.32 1,955.66
19.25% 2.27%
EBITDA Margin 23.78% 22.26%
13.54% 6.40%
Net Margin 2.65% 7.99%
150.26% 201.04%

12 Analysts have issued a sales forecast Astellas Pharma 2026 . The average Astellas Pharma sales estimate is

JPY2.0t
Unlock
. This is
2.27% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
JPY2.0t 5.03%
Unlock
, the lowest is
JPY1.9t 0.55%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 JPY1.9t 19.25%
2026
JPY2.0t 2.27%
Unlock
2027
JPY2.1t 5.41%
Unlock
2028
JPY1.9t 8.80%
Unlock
2029
JPY1.7t 11.08%
Unlock
2030
JPY1.5t 7.64%
Unlock

10 Analysts have issued an Astellas Pharma EBITDA forecast 2026. The average Astellas Pharma EBITDA estimate is

JPY435b
Unlock
. This is
4.29% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
JPY547b 20.18%
Unlock
, the lowest is
JPY362b 20.36%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 JPY455b 35.39%
2026
JPY435b 4.29%
Unlock
2027
JPY511b 17.41%
Unlock
2028
JPY477b 6.73%
Unlock
2029
JPY395b 17.19%
Unlock
2030
JPY260b 34.11%
Unlock

EBITDA Margin

2025 23.78% 13.54%
2026
22.26% 6.40%
Unlock
2027
24.79% 11.37%
Unlock
2028
25.35% 2.26%
Unlock
2029
23.61% 6.86%
Unlock
2030
16.85% 28.63%
Unlock

6 Astellas Pharma Analysts have issued a net profit forecast 2026. The average Astellas Pharma net profit estimate is

JPY156b
Unlock
. This is
208.16% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
JPY204b 302.96%
Unlock
, the lowest is
JPY120b 137.30%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 JPY50.8b 198.42%
2026
JPY156b 208.05%
Unlock
2027
JPY212b 35.55%
Unlock
2028
JPY149b 29.92%
Unlock
2029
JPY154b 4.02%
Unlock
2030
JPY151b 2.53%
Unlock

Net Margin

2025 2.65% 150.26%
2026
7.99% 201.04%
Unlock
2027
10.28% 28.66%
Unlock
2028
7.90% 23.15%
Unlock
2029
9.24% 16.96%
Unlock
2030
9.75% 5.52%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Earnings Per Share JPY 28.35 87.33
198.42% 208.04%
P/E 16.69
EV/Sales 1.66

6 Analysts have issued a Astellas Pharma forecast for earnings per share. The average Astellas Pharma EPS is

JPY87.33
Unlock
. This is
208.15% higher
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
JPY114.20 302.96%
Unlock
, the lowest is
JPY67.25 137.30%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 JPY28.35 198.42%
2026
JPY87.33 208.04%
Unlock
2027
JPY118.37 35.54%
Unlock
2028
JPY82.95 29.92%
Unlock
2029
JPY86.29 4.03%
Unlock
2030
JPY84.10 2.54%
Unlock

P/E ratio

Current 51.44 75.45%
2026
16.69 67.55%
Unlock
2027
12.32 26.18%
Unlock
2028
17.58 42.69%
Unlock
2029
16.90 3.87%
Unlock
2030
17.34 2.60%
Unlock

Based on analysts' sales estimates for 2026, the Astellas Pharma stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.70 19.05%
2026
1.66 2.15%
Unlock
2027
1.58 5.13%
Unlock
2028
1.73 9.64%
Unlock
2029
1.95 12.46%
Unlock
2030
2.11 8.27%
Unlock

P/S ratio

Current 1.37 18.93%
2026
1.33 2.22%
Unlock
2027
1.27 5.12%
Unlock
2028
1.39 9.64%
Unlock
2029
1.56 12.46%
Unlock
2030
1.69 8.27%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today